Sy Pretorius, MD

Industry benefits from heightened innovation, site/sponsor relationships, and diversity.

An examination of recent failures in Phase III studies and innovative approaches to reduce risk.

A high-quality medical infrastructure and low costs make South Africa--largely an untapped opportunity--an attractive alternative for conducting clinical trials.